Research Outputs

Permanent URI for this communityhttps://hdl.handle.net/20.500.14288/2

Browse

Filters

2013 - 2019152020 - 20248

Advanced Search

Filter by

Settings

Quartile: search.filters.quartile.Q2Subject: search.filters.subject.Hematology

Search Results

Now showing 1 - 10 of 23
  • Placeholder
    PublicationMetadata only
    Angiopoietin as a novel prognostic marker in kidney disease
    (KARGER, 2024) Gaipov, Abduzhappar; Magagnoli, Lorenza; Ciceri, Paola; Cozzolino, Mario; Yıldız, Abdullah Burak; Çöpür, Sidar; Tanrıöver, Cem; Yavuz, Furkan; Vehbi, Sezan; Kanbay, Mehmet; School of Medicine
    Introduction: Renal injury is among the leading causes of morbidity and mortality; however, there are no reliable indicators for determining the likelihood of developing chronic kidney disease (CKD), CKD progression, or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization, and inflammation and have been implicated as prognostic and predictive markers in AKI. Methods: Although the exact mechanism of the relationship between kidney injury and angiopoietins is unknown, this review demonstrates that AKI patients have higher angiopoietin-2 levels and that higher angiopoietin-1 to angiopoietin-2 ratio may potentially be linked with a reduced risk of the CKD progression. Results: This review therefore emphasizes the importance of angiopoietin-2 and proposes that it could be an important predictor of AKI in clinical settings. Conclusion: There is a need for further large-scale randomized clinical trials in order to have a better understanding of the significance of angiopoietin-2 and for the determination of its potential clinical implications.
  • Placeholder
    PublicationMetadata only
    Breast metastases in rhabdomyosarcoma: a case series
    (Wiley, 2015) Kebudi, R.; Koç, B.; Görgün, O.; Bay, S. Büyükkapu; Çakır, F. B.; Sözmen, Banu Oflaz; Faculty Member; School of Medicine; 198711
    Metastasis to the breast in the pediatric age group is extremely rare. After leukemia and lymphoma, rhabdomyosarcoma and neuroblastoma are the most common tumors to metastasize to the breast in this age group. Without a known primary, the diagnosis can be a challange. Here, a pediatric patient with widespread metastases to both breasts from embryonal rhabdomyosarcoma imaged by ultrasound and magnetic resonance is presented.
  • Placeholder
    PublicationMetadata only
    Childhood ganglioneuromas
    (Wiley, 2016) Kebudi, R.; Çakır, F. B.; Görgün, O.; Bilgiç, B.; Sözmen, Banu Oflaz; Faculty Member; School of Medicine; 198711
    N/A
  • Placeholder
    PublicationMetadata only
    Children with neuroendocrine tumors presenting with opsoclonus myoclonus syndrome
    (Wiley-Blackwell, 2016) Kebudi, R.; Uysal, S.; Eroğlu, E.; Sözmen, Banu Oflaz; Faculty Member; School of Medicine; 198711
    N/A
  • Placeholder
    PublicationMetadata only
    City of shadows: slums and informal work in Bangalore
    (Routledge Journals, Taylor & Francis Ltd, 2023) Uçar, Canan; Graduate School of Social Sciences and Humanities
  • Placeholder
    PublicationMetadata only
    Colchicine in renal medicine: new virtues of an ancient friend
    (Karger Publishers, 2017) Solak, Yalçın; Siriopol, Dimitrie; Yildiz, Abdulmecit; Yilmaz, Mahmut Ilker; Ortiz, Alberto; Covic, Adrian; N/A; Kanbay, Mehmet; Faculty Member; School of Medicine; 110580
    Colchicine is a plant-derived alkaloid that disrupts the cell microtubule system and accumulates in neutrophils, inhibiting neutrophil adhesion and recruitment. Colchicine has been used extensively in the prevention and treatment of gouty arthritis attacks, familial Mediterranean fever attacks and resultant AA amyloidosis, and recurrent pericarditis. Colchicine also disrupts the intracellular traffic of additional inflammatory and fibrosis mediators. Renal fibrosis is the final common pathway of chronic renal disease. Colchicine had anti-fibrotic effects in experimental diabetic nephropathy, renal mass reduction, and cyclosporine nephrotoxicity among others and is undergoing clinical trials for non-diabetic metabolic syndrome and diabetic nephropathy. In this review, we summarize the anti-inflammatory and anti-fibrotic properties of colchicine in experimental and clinical studies in renal diseases or other fibrotic disease processes with renal consequences. We also discuss the potential future uses of colchicine in renal medicine and challenges faced with its use in patients with impaired kidney function.
  • Placeholder
    PublicationMetadata only
    Comparative analysis of autophagy in drug responses and aggressive behavior of adult versus pediatric glioma cell lines
    (Wiley, 2022) Aygun, Bera; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; Yenidoğan, İrem; Peker, Nesibe; Deveci, Gamze; Kırmızı, Döndü; Asarcıklı, Fikret; Sözmen, Banu Oflaz; Akyoldaş, Göktuğ; Kulaç, İbrahim; Solaroğlu, İhsan; Erbey, Mehmet Fatih; Gözüaçık, Devrim; Researcher; Researcher; PhD Student; Other; Doctor; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; Faculty Member; N/A; Koç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM); N/A; N/A; N/A; N/A; N/A; N/A; N/A; N/A; School of Medicine; N/A; Graduate School of Health Sciences; N/A; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; Koç University Hospital; N/A; N/A; N/A; N/A; N/A; 327591; N/A; N/A; N/A; N/A; 198711; 203677; 102059; 206213; 40248
    Central nervous system tumors are the most common solid cancer and a leading cause of cancer-related deaths in children. Glioma is the most challenging pediatric CNS tumor with therapy resistance and poor prognosis in pediatric patients. Although histopathological analyses revealed similarities with adult brain glioma, emerging evidence suggests that the deregulated molecular pathways in pediatric glioma (p-GM) are different from that of adults. Autophagy, a cellular clearance system and a drug resistance mechanism, has been implicated in glioma progression, invasion, and relapse, yet its role in pediatric patients is not well documented. In this study, we compared the autophagic capacity of adult versus p-GM cell lines and evaluated the effect of autophagy manipulation on drug responses. In addition, migration, extracellular matrix invasion ability, and the metabolism of pediatric and adult gliomas were compared and the contribution of autophagy to the aggressive phenotype was evaluated.
  • Placeholder
    PublicationMetadata only
    Concurrent extrarenal nephroblastoma and neuroblastoma in an infant
    (Wiley, 2014) Kebudi, R.; Büyükünal, C.; Karaca, I.; Kurugoglu, S.; Dervişoğlu, S.; Sözmen, Banu Oflaz; Faculty Member; School of Medicine; 198711
    N/A
  • Placeholder
    PublicationMetadata only
    Continuous venovenous hemodiafiltration in the treatment of maple syrup urine disease
    (Karger, 2016) Sık, Güntülü; Topal, Nilüfer; Çitak, Agop; Zeybek, Çiğdem; Tüten, Abdulhamit; N/A; N/A; Demirkol, Demet; Bilge, İlmay; Faculty Member; Faculty Member; School of Medicine; School of Medicine; 108964; 198907
    Background: The study aims to define the efficacy of continuous renal replacement therapy in acute metabolic decompensation treatment of maple syrup urine disease (MSUD). Methods: All the neonates, infants and children who have had life threatening conditions due to MSUD and were treated with continuous venovenous hemodiafiltration (CVVHDF) were analyzed retrospectively. Results: Fourteen patients underwent 15 sessions of CVVHDF (age range 15 days to 87 months, mean 40.8 +/- 31.4 months). One patient required additional CVVHDF 1 week after cessation of CVVHDF. Twenty seven percent (n = 4) of the patients were intubated and mechanically ventilated. Twelve patients responded to treatment and dramatic neurological improvement was observed within 24 h. Two of the 14 patients required 36 h of CVVHDF for neurological improvement. The mean duration of CVVHDF was 20.2 +/- 8.6 (9-36) h. The mean leucine level was 1,648 +/- 623.8 (714-2,768) mu mol/l before and was 256.5 +/- 150.6 (117-646) mu mol/l at the end of treatment. No mortality was observed. Conclusion: Continuous hemodiafiltration is an effective and safe method in correcting metabolic disturbances in MSUD. (C) 2016 S. Karger AG, Basel
  • Placeholder
    PublicationMetadata only
    Convalescent blood: current perspective on the efficacy of a legacy approach in COVID-19 treatment
    (Karger Publishers, 2022) Sheervalilou, Roghayeh; Shirvaliloo, Milad; Sargazi, Saman; Bahari, Soraiya; Saravani, Ramin; Shahraki, Jafar; Shirvalilou, Sakine; Shahraki, Omolbanin; Shams, Zinat; Ghaznavi, Habib; N/A; Nazarlou, Ziba; PhD Student; Graduate School of Sciences and Engineering; N/A
    Since early 2020, COVID-19 has wreaked havoc in many societies around the world. As of the present, the SARS-CoV-2-borne disease is propagating in almost all countries, affecting hundreds of thousands of people in an unprecedented way. As the name suggests, the novel coronavirus, widely known as SARS-CoV-2, is a new emerging human pathogen. A novel disease of relatively unknown origin, COVID-19 does not seem to be amenable to the currently available medicines since there is no specific cure for the disease. In the absence of any vaccine or effective antiviral medication, we have no tools at our disposal, but the method of quarantine, be it domestic or institutional, to hinder any further progression of this outbreak. However, there is a record of physicians in the past who practiced convalescent blood transfusion. To their awe, the method seemed to be useful. It is anticipated that these contemporary methods will outdo any other vaccination process in the time being, as blood transfusion is instead a cost-effective and time-friendly technique. Following a successful trial, this new approach of contemporary nature to a viral disease may serve as an emergency intervention to intercept infectious outbreaks and prevent an impending epidemic/pandemic. In this review, we document the most recent evidence regarding the efficiency of convalescent plasma and serum therapy on SARS, MERS, and particularly COVID-19, while discussing potential advantages and possible risks of such practice.